U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096908) titled 'Tirzepatide Use in People With Obesity and Type 1 Diabetes' on June 25.
Brief Summary: Tirzepatide, a gut hormone-based medication, has shown promising results in treating obesity, with ~22% weight loss and mild side effects. However, patients with type 2 diabetes typically experience only about 15% weight loss with tirzepatide, despite tolerating the medication well. Its effects in people with both obesity and type 1 diabetes remain largely unknown.
Although tirzepatide is not approved for glycemic control in type 1 diabetes, it is licensed for obesity treatment in Gulf and Europe. In Kuwait, more than a quarter of people with type...